# Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)

> **NCT04245748** · PHASE4 · RECRUITING · sponsor: **University of Cincinnati** · enrollment: 84 (estimated)

## Conditions studied

- Anxious Depression
- Depression

## Interventions

- **DRUG:** Escitalopram
- **DRUG:** Duloxetine

## Key facts

- **NCT ID:** NCT04245748
- **Lead sponsor:** University of Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-03-01
- **Primary completion:** 2025-07-30
- **Final completion:** 2025-12-31
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2024-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04245748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04245748, "Determining Optimal Treatment Sequences in Anxious Depression (DOTS-AD)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04245748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*